Does Anthem Cover Mounjaro?
The verdict
Conditional on most plans
Anthem (Elevance Health) covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, Medicare Advantage, and Medicaid lines via CarelonRx. Mounjaro is not covered for weight loss regardless of employer benefit design. The weight-loss tirzepatide product is Zepbound, which Anthem treats as an employer-optional anti-obesity benefit rider — separate from and unrelated to Mounjaro's diabetes coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Anthem using your member ID.
Key facts
Anthem (Elevance Health) uses CarelonRx as its PBM across 14 states. For type 2 diabetes, Mounjaro PA requires A1c of 6.5% or higher and documented metformin step therapy via CarelonRx.
Anthem/Elevance Health, CarelonRx formulary and PA criteria, 2025-2026
Anthem covers Mounjaro for T2D broadly across all plan lines; Zepbound (weight-loss tirzepatide) requires the employer to have purchased Anthem's optional anti-obesity medication (AOM) benefit rider.
Anthem/Elevance Health, Anti-Obesity Medication benefit overview
The 2026 Medicare Part D out-of-pocket cap is $2,100; most continuous Mounjaro users reach it within 2-3 months and pay $0 for the rest of the year.
CMS.gov, Medicare Part D Redesign 2025-2026
Medicare vs. commercial coverage
Whether Anthem covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Anthem Medicare Advantage and Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — at a specialty or non-preferred brand tier, with prior authorization via CarelonRx. The 2026 Part D out-of-pocket cap is $2,100; most continuous users for diabetes reach it within 2-3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month), which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare or Medicare Advantage beneficiaries.
Commercial / Employer
Group & marketplace plans
Anthem commercial and employer-sponsored plans cover Mounjaro for type 2 diabetes with prior authorization and metformin step therapy via CarelonRx; tier varies (preferred or non-preferred brand) across Anthem's 14-state BCBS licensee footprint. Mounjaro is not covered for off-label weight loss regardless of whether the employer has purchased the anti-obesity medication (AOM) benefit. ACA/Individual: Anthem ACA plans cover Mounjaro for T2D with PA; weight-loss GLP-1s are commonly excluded. Medicaid: Anthem Medicaid managed-care state plans cover Mounjaro for T2D with PA and nominal cost-share; weight-loss coverage is state-dependent. Lilly savings card: $25/month for commercially insured with coverage; $499/month without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare, Medicaid, or government program beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Varies by Anthem regional plan and CarelonRx tier; preferred or non-preferred brand cost-share. Commercially insured with coverage may pay as little as $25/month via Lilly savings card. Medicare Part D: 25% coinsurance to $2,100 OOP cap 2026; MFN $245/month mid-2026. Medicaid: nominal cost-share.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) applies only to weight-loss-approved products. Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; actual cost-share varies by Anthem regional plan and PBM tier. Verify on the Anthem drug lookup tool or call member services. Lilly savings card expires 12/31/2026.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the Anthem drug lookup tool for your regional plan
Visit anthem.com and navigate to your specific plan's formulary or drug lookup. Enter 'Mounjaro' or 'tirzepatide'. Because Anthem operates across 14 states as a BCBS licensee, tier placement may vary by region (e.g., Anthem in California vs. Virginia vs. Ohio). Note the tier and PA requirement.
- 2
Have your prescriber submit the CarelonRx prior authorization
Your prescriber needs to document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior metformin use or contraindication. CarelonRx (Anthem's PBM) processes the PA. Your prescriber should submit via the CarelonRx PA portal; allow up to 72 hours for standard review.
- 3
Check whether your employer has the anti-obesity benefit rider for Zepbound
If you are looking for weight-loss tirzepatide (Zepbound, not Mounjaro), ask your HR department whether your employer has purchased the anti-obesity medication (AOM) benefit rider through Anthem. Mounjaro is not a substitute — it is covered only for confirmed T2D, not weight management.
Options if Anthem won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Frequently at a preferred or non-preferred brand tier through CarelonRx for Anthem plans with prior authorization.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative with lower list price than Mounjaro; often preferred tier across Anthem's CarelonRx formularies.
Jardiance (empagliflozin)
SGLT2 inhibitor approved for T2D. Often on preferred tiers for Anthem commercial and Medicare Advantage plans; may be part of step therapy.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea. Anthem treats Zepbound as an employer-optional AOM benefit rider — separate from T2D coverage. If your employer purchased the AOM benefit, Zepbound may be covered with PA. If not, it is excluded. This is entirely separate from Mounjaro's diabetes coverage.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. Anthem does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only; off-label weight-loss requests coded with obesity diagnoses are denied regardless of employer benefit design. For weight loss, the same active ingredient (tirzepatide) is Zepbound — an entirely separate product with separate, often employer-dependent coverage. Anthem's AOM benefit for Zepbound is an optional employer rider and does not affect Mounjaro's diabetes-only coverage.
CarelonRx is Anthem's in-house PBM and manages the prior authorization and tier placement for Mounjaro across Anthem's commercial, Medicare Advantage, and Medicaid plans. For T2D, CarelonRx standard PA requires documented A1c of 6.5% or higher and metformin step therapy. Tier varies by Anthem regional plan (preferred or non-preferred brand). Verify your specific tier and step-therapy criteria on the Anthem drug lookup tool or CarelonRx formulary.
Mounjaro and Zepbound contain the same active ingredient, tirzepatide, but have different FDA approvals and entirely different coverage pathways at Anthem. Mounjaro is FDA-approved for type 2 diabetes — covered with a standard PA for T2D patients across all Anthem lines. Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea — covered only if the employer has purchased Anthem's optional anti-obesity medication benefit rider. One plan can cover Mounjaro for diabetes while excluding Zepbound for weight loss in the same plan year.
Yes, if you have commercial Anthem coverage (employer-sponsored or ACA). The Lilly Mounjaro Savings Card provides as little as $25/month for commercially insured members with Mounjaro coverage, and $499/month (up to $647/month, 13 fills, expires 12/31/2026) without coverage. The card is not available to Anthem Medicare Advantage, Medicaid, or any government-program beneficiaries.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is a diabetes drug. Anthem Medicare Advantage covers Mounjaro under standard Part D for T2D only, with PA, specialty-tier cost-share, and the $2,100 annual OOP cap.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Mounjaro? HCSC 2026 | Curex
BCBS of Illinois (HCSC) covers Mounjaro for type 2 diabetes with PA — not weight loss. IL Medicaid covers T2D but excludes weight-loss GLP-1s.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
You just saw how tangled Mounjaro coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Mounjaro. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Anthem before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.